Could a short, High-Dose drug course cure small pituitary tumors?
NCT ID NCT07463235
First seen Mar 15, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This study tests whether a higher dose of the drug cabergoline, taken for about 6 months, can achieve lasting remission in women with small prolactinomas (non-cancerous pituitary tumors that cause excess prolactin). 70 premenopausal women will be randomly assigned to either the high-dose short course or standard long-term low-dose treatment. The goal is to see if the high-dose approach leads to normal prolactin levels for at least a year after stopping the drug, potentially avoiding years of daily medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLACTINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CPC
RECRUITINGPonta Grossa, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HCFMUSP
RECRUITINGSão Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HCPA
COMPLETEDPorto Alegre, Brazil
-
Hospital Moinhos de Vento
RECRUITINGPorto Alegre, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sta Casa-RS
RECRUITINGPorto Alegre, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sta Casa-SP
RECRUITINGSão Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UFG
RECRUITINGGoiânia, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UFMG
RECRUITINGBelo Horizonte, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UFPE
RECRUITINGRecife, Brazil
Contact Email: •••••@•••••
-
UFPR
RECRUITINGCuritiba, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UFRJ
RECRUITINGRio de Janeiro, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UNB
RECRUITINGBrasília, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USP-RP
RECRUITINGRibeirão Preto, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Unesp
RECRUITINGBotucatu, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Unicamp
RECRUITINGCampinas, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Unifesp
RECRUITINGSão Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabergoline (a drug that lowers prolactin levels)
What this could lead to
If successful, this could offer a shorter, more effective treatment course for small prolactinomas, potentially allowing women to stop medication sooner without the tumor returning.
What could go wrong
This is a relatively small, early-phase trial (70 participants) and the high dose may cause more side effects. Remission may not be permanent, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.